Syntara Ltd
ASX:SNT

Watchlist Manager
Syntara Ltd Logo
Syntara Ltd
ASX:SNT
Watchlist
Price: 0.078 AUD -2.5% Market Closed
Market Cap: 123.2m AUD

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Syntara Ltd

Revenue
5.4m AUD
Operating Expenses
-19.5m AUD
Operating Income
-14.1m AUD
Other Expenses
-1.1m AUD
Net Income
-15.1m AUD

Margins Comparison
Syntara Ltd Competitors

Country Company Market Cap Operating
Margin
Net
Margin
AU
Syntara Ltd
ASX:SNT
123.2m AUD
-259%
-279%
US
Eli Lilly and Co
NYSE:LLY
770.8B USD
38%
24%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
-4%
US
Johnson & Johnson
NYSE:JNJ
391.9B USD
26%
16%
DK
Novo Nordisk A/S
CSE:NOVO B
2.4T DKK
48%
35%
CH
Roche Holding AG
SIX:ROG
243.8B CHF
32%
20%
UK
AstraZeneca PLC
LSE:AZN
186B GBP
23%
13%
US
Merck & Co Inc
NYSE:MRK
239.5B USD
36%
27%
CH
Novartis AG
SIX:NOVN
195.1B CHF
32%
23%
IE
Endo International PLC
LSE:0Y5F
158.2B USD
11%
-126%
US
Pfizer Inc
NYSE:PFE
145.7B USD
25%
13%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Syntara Ltd Competitors

Country Company Market Cap ROE ROA ROCE ROIC
AU
Syntara Ltd
ASX:SNT
123.2m AUD
-212%
-88%
-134%
-222%
US
Eli Lilly and Co
NYSE:LLY
770.8B USD
85%
15%
39%
22%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
US
Johnson & Johnson
NYSE:JNJ
391.9B USD
20%
8%
19%
14%
DK
Novo Nordisk A/S
CSE:NOVO B
2.4T DKK
81%
26%
71%
33%
CH
Roche Holding AG
SIX:ROG
243.8B CHF
40%
13%
29%
22%
UK
AstraZeneca PLC
LSE:AZN
186B GBP
18%
7%
17%
14%
US
Merck & Co Inc
NYSE:MRK
239.5B USD
42%
15%
28%
21%
CH
Novartis AG
SIX:NOVN
195.1B CHF
27%
12%
23%
17%
IE
Endo International PLC
LSE:0Y5F
158.2B USD
70%
-51%
5%
6%
US
Pfizer Inc
NYSE:PFE
145.7B USD
9%
4%
9%
8%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.